Monthly research recap
Psilocybin research: October 2026
What October 2026's 25 new studies found, synthesized from the papers below. All Psilocybin research →
The synthesis
Synthesized from 25 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Psilocybin, magic mushrooms, psilocin, psychedelic mushrooms, then ranked by relevance.
Research indexed in October 2026 on psilocybin was broad and mostly early-stage: small randomized and pilot trials in treatment-resistant depression and alcohol use disorder suggested possible short-term benefit, but primary endpoints were often missed and durability was uncertain. A meta-analysis in alcohol use disorder found moderate short-term advantages over controls that largely faded at longer follow-up, and observational retreat data showed sustained wellbeing gains over 12 months without causal proof. Mechanistic animal and primate work pointed to 5-HT2A and 5-HT1B receptor and network-level effects, while safety reviews found low psychosis risk in supervised settings. The main caveats are small samples, post hoc or secondary analyses, and limited long-term and controlled data.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Effects of psilocybin with psychological support on anhedonia in treatment-resistant depression: A randomized controlled pilot trial. 2026 | RCT | 20 | Mixed | Psilocybin 25 mg missed the primary week-1 anhedonia endpoint but showed greater anhedonia improvement at week 8 and greater depression severity improvement at weeks 1 and 8. |
| Psilocybin, cognitive stability and drinking reduction in co-occurring alcohol use disorder and depression: a pilot secondary analysis of a randomized, placebo-controlled trial 2026 | secondary analysis of RCT | 25 | Mixed | Psilocybin slowed cued task switching about a week after dosing with no consistent effect on feedback-driven flexibility or willingness to exert control, and drinking reduction was associated with increased cognitive stability. |
| Multi-scale effects of single-dose psilocybin in the macaque brain 2026 | preclinical experimental (non-human primate) | Supports | A single psilocybin dose increased frontoparietal integration with default-mode and limbic networks, induced global network segregation, and produced molecular and metabolic changes lasting about one week. | |
| High-Quality Genome Assembly and Transcriptomic Analysis Reveal Potential Pathways for Psilocybin Biosynthesis in Gymnopilus dilepis 2026 | genomic and transcriptomic analysis | Unclear | Reports a chromosome-level genome assembly and argues that psilocybin biosynthesis in this species is linked to amino acid metabolic pathways that may supply precursors. | |
| Connectedness as a candidate pathway linking psilocybin retreat experiences to sustained wellbeing: a prospective naturalistic study 2026 | observational cohort | 173 | Supports | Participants reported substantial wellbeing improvements sustained over 12 months, with connectedness the strongest correlate and a candidate mediator, though the design precludes causal inference. |
| Psychedelics and psychosis: A systematic review of recent-era studies (1984-2025). 2026 | systematic review | Mixed | Population data showed no consistent link between lifetime psychedelic use and psychosis and controlled trials showed minimal risk, while case reports suggested personal or family psychiatric history and unsupervised use as risk factors. | |
| Sex-related differences in outcomes following psilocybin or escitalopram: a Bayesian secondary analysis. 2026 | post hoc Bayesian reanalysis of RCT | 59 | Mixed | No outcome showed an overall sex difference across treatments; within psilocybin, females had lower post-treatment anxiety than males, but the estimate was prior-sensitive and the sex-by-treatment interaction was inconclusive. |
| Substantial Treatment-Seeking Interest, Narrow Eligibility: Diagnostic Heterogeneity and External Validity in the PRIDE Psilocybin Trial—Relevance to Precision Psychiatry 2026 | cross-sectional descriptive analysis | 67 | Unclear | Of 67 screened candidates, 80.6% were excluded, most often for lacking protocol-defined treatment-resistant depression or having another psychiatric diagnosis, illustrating a gap between trial populations and treatment-seeking individuals. |
| The Post-Acute Window: Suicidal Ideation and Behaviour After Psilocybin. A Rapid Computational Evidence Synthesis 2026 | rapid computational evidence synthesis | Unclear | Public sources do not yet support a window-specific incidence of suicidal ideation or behaviour after psilocybin, and only 3.5% of trial registrations scheduled a suicidality assessment within days 2-21 after dosing. | |
| Psilocybin and Inflammatory and Mitochondrial Stress Markers in Parkinson Disease 2026 | nonrandomized clinical trial | Unclear | The abstract states only that the trial assesses associations between psilocybin therapy and changes in systemic markers of inflammation and mitochondrial stress, with no results reported. | |
| Psilocybin in Treatment-Resistant Depression: Weighing Rapid Antidepressant Effects Against Uncertain Durability 2026 | structured narrative review | Mixed | Concludes that psilocybin with psychological support shows short-term antidepressant activity, with one phase 3 trial meeting its week-3 endpoint while another did not confirm its week-6 response hypothesis, and that specific drug effect and durability remain uncertain. | |
| Investigation of the pharmacological and circuit basis for psychedelic drug effects on interval timing in mice. 2026 | experimental animal study | Supports | Psilocin altered timing accuracy and precision, an effect blocked by a 5-HT2A antagonist but not a 5-HT1A antagonist, and medial prefrontal DOI infusion mimicked systemic effects. | |
| Serotonin 1B receptors expressed on forebrain excitatory neurons mediate the post-acute anxiolytic response to psilocybin in mice. 2026 | controlled animal experiment | Supports | Mice lacking 5-HT1B receptors on forebrain excitatory neurons showed intact acute responses but strongly attenuated post-acute anxiolytic effects of psilocybin, alongside altered brain-wide network synchronization. | |
| Group psilocybin in an integrative retreat setting enhances social connection: an observational case report 2026 | case study | 14 | Supports | Participants showed significant increases in perceived social connectedness and significant decreases in distress after the group ceremony. |
| The Follow-Up Problem in Psilocybin-Assisted Therapy: Integration, Aftercare, and the Missing Standard 2026 | commentary | Unclear | Argues that integration, aftercare, and long-term follow-up in psilocybin-assisted therapy remain poorly defined relative to short-term outcome measurement. | |
| Mechanistic Evaluation of Psilocybin in Neurodegenerative Disorders: Relevance of 5-HT2A Receptors and Downstream Pathways 2026 | review | Supports | Argues that psilocybin shows promise for neurodegenerative disorders via 5-HT2A-mediated neuroplasticity and anti-inflammatory effects, citing preclinical plasticity findings and emerging clinical reports, while calling for randomized trials. | |
| Language-associated brain representations covary with disruption of selfhood under psilocybin 2026 | observational fMRI study | 43 | Supports | Greater similarity in activity of a left-lateralised frontotemporal language network under 19 mg psilocybin was associated with higher ego-dissolution scores. |
| The Hidden Therapeutic Bridge: Exploring Psilocybin’s Role in Depression, Inflammation, and Pain – A Narrative Review 2026 | narrative review | Supports | Argues that psilocybin and psilocin show therapeutic potential for depression, anxiety, and pain, with mechanisms possibly involving inflammation, pain processing, the default mode network, and mystical experiences. | |
| Participant experiences and recommendations for psychedelic clinical trials and future treatment delivery: a qualitative study with experts by experience from the Psychedelic Participant Advocacy Network 2026 | qualitative descriptive study | 4 | Mixed | Participants described trial procedures and research conditions as shaping their experience, viewed dosing as the start of ongoing meaning-making, and reported loss or frustration after study end while recommending structured peer support. |
| Acute anxiogenic effects of psilocybin and the related tryptamine, norbaeocystin, in male and female rats 2026 | animal experiment | Opposes | Psilocybin and norbaeocystin produced acute, dose- and sex-specific increases in anxiety-like behavior, with no effects on elevated plus maze behavior 24 hours later. | |
| Psilocybin enhances conditioned place preference learning in planarians. 2026 | controlled laboratory experiment | Supports | A single 5 µM psilocybin exposure enhanced conditioned place preference learning, with effects persisting at least six days after administration. | |
| Direct Quantitation of Psilocybin and Psilocin by 1H and 31P qNMR in Wild Psilocybe from Greece 2026 | methodological analytical study | Unclear | Reports reference-standard-free qNMR methods for quantifying psilocybin and psilocin in wild Psilocybe mushrooms and documents a psychoactive Psilocybe species from Greece. | |
| Efficacy and safety of psilocybin-assisted therapy for alcohol use disorder: A systematic review and meta-analysis 2026 | systematic review and meta-analysis | 202 | Supports | Across six trials, psilocybin-assisted therapy produced within-group drinking reductions and moderate short-term advantages over controls on several drinking measures, with only percent drinking days still superior at longer follow-up and higher odds of abstinence. |
| Preparing the body for psilocybin therapy: receptive and generative interoception in cancer patients 2026 | theoretical | Unclear | Proposes that preparation for psilocybin therapy in cancer patients neglects the body and offers a taxonomy of somatic experiences plus receptive and generative interoceptive practices to be tested in an ongoing trial. | |
| Psilocybin-assisted psychotherapy for people with cancer: a scoping review of intervention components, psychotherapeutic frameworks, and models of delivery 2026 | scoping review | Unclear | The abstract states only the review's objective of mapping evidence on psilocybin-assisted psychotherapy in cancer, with no results or conclusions reported. |
Points of agreement
- Small trials and reviews in treatment-resistant depression report short-term symptom improvement with psilocybin plus psychological support, though primary endpoints are often missed.
- Meta-analytic and trial evidence in alcohol use disorder points to short-term drinking reductions that attenuate at longer follow-up.
- Animal and primate work consistently implicates serotonin receptor subtypes (5-HT2A, 5-HT1B) and network-level reorganization in psilocybin's acute and post-acute effects.
- Reviews and registry analyses agree that supervised clinical use carries low psychosis risk and that long-term durability and follow-up standards are unresolved.
Conflicts
- Some trials report benefit on secondary depression and anhedonia measures while missing primary endpoints, whereas others find no consistent cognitive or clinical effects.
- Animal studies show acute anxiogenic effects of psilocybin, while clinical and other animal work emphasizes post-acute anxiolytic effects.
- Observational retreat data show sustained 12-month wellbeing gains, while controlled trial reviews emphasize uncertain durability.
Gaps
- Long-term durability beyond weeks to 12 months is largely unestablished.
- Blinding integrity and the specific drug versus psychotherapy effect are unresolved.
- Most clinical samples are small, and females and diverse diagnostic groups are underrepresented.
- Dose-response relationships and retreatment strategies are not well characterized.
- Suicidality monitoring in the post-acute window is rarely pre-specified in trials.
- Randomized controlled trials in neurodegenerative disorders and cancer are lacking.